Apollomics regains Nasdaq listing compliance

Apollomics Inc. reports that Nasdaq has confirmed the company has regained compliance with the Market Value of Listed Securities (MVLS) requirement under Nasdaq Listing Rule 5550(b)(2) for continued listing on the Nasdaq Capital Market.

Rhea-AI Filing Summary

Apollomics Inc. reports that Nasdaq has confirmed the company has regained compliance with the Market Value of Listed Securities (MVLS) requirement under Nasdaq Listing Rule 5550(b)(2) for continued listing on the Nasdaq Capital Market.

Nasdaq staff determined that from June 23, 2026 to July 7, 2026 Apollomics’ MVLS was $35 million or greater for 10 consecutive business days, following an earlier June 18, 2026 notice of non-compliance when MVLS had been below the required $35 million minimum for 30 consecutive business days. The matter is now closed. Apollomics is a late-stage clinical biopharmaceutical company whose lead program, vebreltinib (APL-101), is in a Phase 2 multicohort trial for cancers with c-Met alterations.

Filing Explained

Beyond the previously reported compliance outcome, the July 14 Form 6-K states that its contents are incorporated by reference into Apollomics’ listed S-8 and F-3 registration statements, unless superseded by later filings.

Key Figures

Nasdaq MVLS minimum: $35 million Non-compliance assessment period: 30 consecutive business days Compliance re-evaluation period: 10 consecutive business days +2 more

5 metrics

Nasdaq MVLS minimum $35 million Minimum Market Value of Listed Securities required under Nasdaq Listing Rule 5550(b)(2)

Non-compliance assessment period 30 consecutive business days Period during which Apollomics’ MVLS was below $35 million, leading to a June 18, 2026 deficiency notice

Compliance re-evaluation period 10 consecutive business days From June 23, 2026 to July 7, 2026, MVLS was $35 million or greater, restoring compliance

Non-compliance notice date June 18, 2026 Date Nasdaq notified Apollomics that it was not in compliance with the MVLS rule

Compliance restored notice date July 8, 2026 Date Nasdaq staff confirmed Apollomics had regained MVLS compliance and closed the matter

Key Terms

Market Value of Listed Securities, Nasdaq Capital Market, forward-looking statements, Phase 2 multicohort clinical trial, +1 more

5 terms

Market Value of Listed Securities regulatory

"regained compliance with the Market Value of Listed Securities requirement"

Market value of listed securities is the market value of the shares a company has listed on an exchange, calculated as the closing bid price multiplied by the number of listed shares. Exchanges use it as a continued-listing standard, so a company that stays under the required minimum receives a deficiency notice and is given a set period to recover before facing delisting.

Nasdaq Capital Market regulatory

"for continued listing on the Nasdaq Capital Market after MVLS compliance"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

forward-looking statements regulatory

"This press release includes statements that constitute “forward-looking statements”"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Phase 2 multicohort clinical trial medical

"vebreltinib (APL-101)...currently in a Phase 2 multicohort clinical trial"

Form 20-F regulatory

"risks and uncertainties discussed in the Annual Report on Form 20-F"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

FAQ

What did Apollomics (APLM) announce regarding its Nasdaq listing status?

Apollomics announced it has regained compliance with Nasdaq’s Market Value of Listed Securities requirement, allowing continued listing on the Nasdaq Capital Market. Nasdaq staff confirmed the company met the MVLS threshold for 10 consecutive business days, and the compliance matter is now considered closed.

What is the Nasdaq MVLS requirement affecting Apollomics (APLM)?

The relevant Nasdaq rule requires a minimum Market Value of Listed Securities of $35 million for continued listing on the Nasdaq Capital Market. Apollomics had previously fallen below this threshold but later met or exceeded it for 10 straight business days, restoring compliance.

When was Apollomics (APLM) found out of compliance and when was it restored?

Nasdaq notified Apollomics on June 18, 2026 that it was not in compliance with the $35 million MVLS rule. After maintaining at least $35 million MVLS for 10 consecutive business days, Nasdaq informed the company on July 8, 2026 that compliance had been regained.

Over what period did Apollomics (APLM) meet the MVLS threshold to regain compliance?

Nasdaq staff determined that from June 23, 2026 to July 7, 2026, Apollomics’ market value of listed securities remained at $35 million or greater for 10 consecutive business days, satisfying the MVLS requirement for continued listing on the Nasdaq Capital Market.

What type of company is Apollomics (APLM) and what is its lead program?

Apollomics is described as a late-stage clinical biopharmaceutical company developing oncology therapies. Its lead program is vebreltinib (APL-101), a selective c-Met inhibitor being studied in a Phase 2 multicohort clinical trial for non-small cell lung cancer and other advanced tumors.

Does regaining MVLS compliance affect Apollomics (APLM) Nasdaq Capital Market listing?

Yes. Regaining MVLS compliance supports Apollomics’ continued listing on the Nasdaq Capital Market under Listing Rule 5550(b)(2). Nasdaq’s notice stated the company now satisfies the minimum $35 million market value requirement and the previous deficiency matter is closed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/14/2026 - 07:00 AM Accepted by SEC EDGAR 07/14/2026 - 07:00 AM Learn about SEC filing dates

OMB APPROVAL
OMB Number:				3235-0116
Expires:		December 31, 2026
Estimated average burden
hours per response				8.7

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026.

Commission File Number 001-41670

Apollomics Inc.

Not Applicable

(Translation of registrant’s name into English)

989 E. Hillsdale Blvd., Suite 220, Foster City, California 94404

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☒ Form 20-F    ☐ Form 40-F

Regain of Compliance with a Continued Listing Rule or Standard

On July 8, 2026, Apollomics Inc. (the “Company”) received written notice from the Nasdaq Listing Qualifications Staff (Staff) stating that the Company regained compliance with the Market Value of Listed Securities (MVLS) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (Rule) for continued listing on the Nasdaq Capital Market, and the matter is now closed.

As previously reported, the Company was notified by the Nasdaq Stock Market LLC on June 18, 2026, that it was not in compliance with the Rule because it failed to maintain a minimum MVLS of $35 million over the previous 30 consecutive business days. Since then, Staff has determined that for the last 10 consecutive business days, from June 23, 2026 to July 7, 2026, the Company’s market value of listed securities has been $35 million or greater. Accordingly, the Company has regained compliance with the Rule, and this matter is now closed.

Press Release and Exhibit

The Company issued a press release announcing that it has regained compliance with the Nasdaq minimum MVLS requirement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Form 6-K is incorporated by reference into the Company’s registration statements under the Securities Act of 1933, as amended, including its registration statements on Form S-8 (File Nos. 333-272559 and 333-293148) and Form F-3 (File Nos. 333-278430, 333-278431, 333-279549, and 333-294154), and shall be a part thereof, to the extent not superseded by documents or reports subsequently filed or furnished.

2 of 4

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release dated July 13, 2026

3 of 4

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

APOLLOMICS INC.

(Registrant)

Date July 14, 2026

(Signature)^*

Peter Lin, Chief Financial Officer

*  Print the name and title under the signature of the signing officer.

SEC 1815 (07-22) Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.

4 of 4

Exhibit 99.1

Apollomics Regains Full Compliance with Nasdaq Listing Requirements

FOSTER CITY, CALIF. – July 13, 2026 – Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that on July 8, 2026, it received written notice from the Nasdaq Listing Qualifications Staff (Staff) stating that the Company regained compliance with the Market Value of Listed Securities (MVLS) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (Rule) for continued listing on the Nasdaq Capital Market, and the matter is now closed.

As previously reported, the Company was notified by the Nasdaq Stock Market LLC on June 18, 2026, that it was not in compliance with the Rule because it failed to maintain a minimum MVLS of $35 million over the previous 30 consecutive business days. Since then, Staff has determined that for the last 10 consecutive business days, from June 23, 2026 to July 7, 2026, the Company’s market value of listed securities has been $35 million or greater. Accordingly, the Company has regained compliance with the Rule, and this matter is now closed.

About Apollomics Inc.

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries.

For more information, please visit www.apollomicsinc.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives and anticipated outcomes from the development and commercialization of vebreltinib are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2025, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law.

Investor Contacts

Peter Lin, Chief Financial Officer

Apollomics, Inc.

1-650-209-4055

peter.lin@apollomicsinc.com

Peter Vozzo

ICR Healthcare

1-443-213-0505

Peter.Vozzo@icrhealthcare.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 7.7 KB